Literature DB >> 33442380

Nuclear Factor Erythroid 2 Related Factor 2 Activator JC-5411 Inhibits Atherosclerosis Through Suppression of Inflammation and Regulation of Lipid Metabolism.

Xinhai Jiang1, Yining Li1, Weizhi Wang1, Xiaowan Han1, Jiangxue Han1, Mingzhu Chen1, Jing Zhang1, Chenyin Wang1, Shunwang Li1, Jinque Luo1, Xiao Wang1, Yang Xu1, Yanni Xu1, Jingcai Cheng2, Shuyi Si1.   

Abstract

Phenethyl isothiocyanate is widely present in cruciferous vegetables with multiple biological effects. Here we reported the antiatherogenic effects and the underlying mechanisms of JC-5411 (Phenethyl isothiocyanate formulation) in vitro and in vivo. Luciferase reporter assay showed that JC-5411 increased the activity of nuclear factor erythroid 2-related factor 2 (Nrf2) and antioxidant response element (ARE). JC-5411 treatment significantly increased the protein expression of Nrf2 and its downstream target gene hemeoxygenase 1 (HO-1) in liver of apolipoprotein E deficient (ApoE-/-) mice. Importantly, JC-5411 treatment significantly reduced atherosclerotic plaque area in both en face aorta and aortic sinus when compared with model group in WD induced ApoE-/- mice. JC-5411 obviously decreased proinflammatory factors' levels in serum of ApoE-/- mice, LPS stimulated macrophages and TNFα induced endothelial cells, respectively. JC-5411 significantly decreased the levels of total cholesterol (TC) and triglyceride (TG) in both serum and liver of ApoE-/- mice and hyperlipidemic golden hamsters. Mechanism studies showed that JC-5411 exerted anti-inflammatory effect through activating Nrf2 signaling and inhibiting NF-κB and NLRP3 inflammasome pathway. JC-5411 exerted regulating lipid metabolism effect through increasing cholesterol transfer proteins (ABCA1 and LDLR) expression, regulating fatty acids synthesis related genes (p-ACC, SCD1 and FAS), and increasing fatty acids β-oxidation (CPT1A) in vivo. Furthermore, JC-5411 treatment had a favorable antioxidant effect in ApoE-/- mice by increasing the antioxidant related genes expression. Taken together, we conclude that JC-5411 as a Nrf2 activator has anti-inflammatory, rebalancing lipid metabolism, and antioxidant effects, which makes it as a potential therapeutic agent against atherosclerosis.
Copyright © 2020 Jiang, Li, Wang, Han, Han, Chen, Zhang, Wang, Li, Luo, Wang, Xu, Xu, Cheng and Si.

Entities:  

Keywords:  JC-5411; Phenethyl isothiocyanate; atherosclerosis; inflammation; nuclear factor erythroid 2-related factor 2

Year:  2020        PMID: 33442380      PMCID: PMC7797784          DOI: 10.3389/fphar.2020.532568

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  59 in total

1.  Dietary Nrf2 activators inhibit atherogenic processes.

Authors:  Bernhard H J Juurlink
Journal:  Atherosclerosis       Date:  2012-09-03       Impact factor: 5.162

Review 2.  Oxidative Stress in Atherosclerosis.

Authors:  Ajoe John Kattoor; Naga Venkata K Pothineni; Deepak Palagiri; Jawahar L Mehta
Journal:  Curr Atheroscler Rep       Date:  2017-09-18       Impact factor: 5.113

Review 3.  Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases.

Authors:  Antonio Cuadrado; Ana I Rojo; Geoffrey Wells; John D Hayes; Sharon P Cousin; William L Rumsey; Otis C Attucks; Stephen Franklin; Anna-Liisa Levonen; Thomas W Kensler; Albena T Dinkova-Kostova
Journal:  Nat Rev Drug Discov       Date:  2019-04       Impact factor: 84.694

Review 4.  Cholesterol transport system: An integrated cholesterol transport model involved in atherosclerosis.

Authors:  Xiao-Hua Yu; Da-Wei Zhang; Xi-Long Zheng; Chao-Ke Tang
Journal:  Prog Lipid Res       Date:  2018-12-04       Impact factor: 16.195

Review 5.  Progress and challenges in translating the biology of atherosclerosis.

Authors:  Peter Libby; Paul M Ridker; Göran K Hansson
Journal:  Nature       Date:  2011-05-19       Impact factor: 49.962

6.  The absence of macrophage Nrf2 promotes early atherogenesis.

Authors:  Anna-Kaisa Ruotsalainen; Matias Inkala; Mervi E Partanen; Jari P Lappalainen; Emilia Kansanen; Petri I Mäkinen; Suvi E Heinonen; Heidi M Laitinen; Janne Heikkilä; Tero Vatanen; Sohvi Hörkkö; Masayuki Yamamoto; Seppo Ylä-Herttuala; Matti Jauhiainen; Anna-Liisa Levonen
Journal:  Cardiovasc Res       Date:  2013-01-22       Impact factor: 10.787

7.  Osteocalcin improves nonalcoholic fatty liver disease in mice through activation of Nrf2 and inhibition of JNK.

Authors:  Jing Du; Mingliang Zhang; Junxi Lu; Xueli Zhang; Qin Xiong; Yiting Xu; Yuqian Bao; Weiping Jia
Journal:  Endocrine       Date:  2016-03-19       Impact factor: 3.633

Review 8.  The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis.

Authors:  Masayuki Yamamoto; Thomas W Kensler; Hozumi Motohashi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

Review 9.  Crosstalk between Nrf2 and the proteasome: therapeutic potential of Nrf2 inducers in vascular disease and aging.

Authors:  Sarah J Chapple; Richard C M Siow; Giovanni E Mann
Journal:  Int J Biochem Cell Biol       Date:  2012-05-07       Impact factor: 5.085

10.  Nrf2 Activation Provides Atheroprotection in Diabetic Mice Through Concerted Upregulation of Antioxidant, Anti-inflammatory, and Autophagy Mechanisms.

Authors:  Iolanda Lazaro; Laura Lopez-Sanz; Susana Bernal; Ainhoa Oguiza; Carlota Recio; Ana Melgar; Luna Jimenez-Castilla; Jesus Egido; Julio Madrigal-Matute; Carmen Gomez-Guerrero
Journal:  Front Pharmacol       Date:  2018-07-31       Impact factor: 5.810

View more
  3 in total

1.  Direct Inhibition of GSDMD by PEITC Reduces Hepatocyte Pyroptosis and Alleviates Acute Liver Injury in Mice.

Authors:  Jie Wang; Ke Shi; Ning An; Shuaifei Li; Mei Bai; Xudong Wu; Yan Shen; Ronghui Du; Jingcai Cheng; Xuefeng Wu; Qiang Xu
Journal:  Front Immunol       Date:  2022-01-31       Impact factor: 7.561

Review 2.  The Role of NRF2 in Obesity-Associated Cardiovascular Risk Factors.

Authors:  Jorge Gutiérrez-Cuevas; Marina Galicia-Moreno; Hugo Christian Monroy-Ramírez; Ana Sandoval-Rodriguez; Jesús García-Bañuelos; Arturo Santos; Juan Armendariz-Borunda
Journal:  Antioxidants (Basel)       Date:  2022-01-26

3.  Association of Circulating Heme Oxygenase-1, Lipid Profile and Coronary Disease Phenotype in Patients with Chronic Coronary Syndrome.

Authors:  Chiara Caselli; Raffaele De Caterina; Rosetta Ragusa; Riccardo Liga; Alessia Gimelli; Arthur J H A Scholte; Aldo Clerico; Juhani Knuuti; Danilo Neglia
Journal:  Antioxidants (Basel)       Date:  2021-12-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.